Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study.

ABSTRACT:

Background

Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is common in intensive care units (ICUs), yet optimal amikacin dosing in this context remains poorly understood.

Methods

We conducted a prospective observational study across 18 French hospitals from April 2020 to January 2022. Adult ICU patients (aged > 18 years) receiving their first amikacin dose while on RRT were included. Data on demographics, RRT modalities, amikacin dosing, and therapeutic drug monitoring were collected. Using a pharmacokinetic modeling approach, we evaluated various amikacin regimens and simulated target attainment probabilities across different minimum inhibitory concentrations (MICs).

Results

A total of 111 patients were included, with approximately two-thirds rec

SUBMITTER: Dupont V 

PROVIDER: S-EPMC11937451 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature